Showing results (161-170 of 293) with videos related to

Sort By:
Pageof 30
Journal of Pharmaceutical and Biomedical Analysis|July 14, 2020
Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC-MS/MSJulianne L Holleran, Robert A Parise, Jianxia Guo, et al.
Frontiers in Immunology|July 12, 2021
Transcriptional Profiling of Monocytes Deficient in Nuclear Orphan Receptors <i>NR4A2</i> and <i>NR4A3</i> Reveals Distinct Signalling Roles Related to Antigen Presentation and Viral ResponseDavid E Phelan, Masahiko Shigemura, Sarah Aldhafiri, et al.
The Journal of Biological Chemistry|December 3, 2010
Small ubiquitin-related modifier (SUMO)-1 promotes glycolysis in hypoxiaTerence A Agbor, Alex Cheong, Katrina M Comerford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2015
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeLesley Seymour, Susan Groshen, Gary L Rosner, et al.
Wilderness & Environmental Medicine|March 12, 2025
Survey of Pathologic Microorganisms in the Streams Along the Tahoe Rim TrailHannah A Miller, Robby S Boparai, Joshua J Warner, et al.
Reviews of Infectious Diseases|May 1, 1984
A comparison of the serologic responses to oral and injectable trivalent poliovirus vaccinesA M McBean, M L Thoms, R H Johnson, et al.
Investigational New Drugs|January 19, 2010
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsJoleen Hubbard, Charles Erlichman, David O Toft, et al.
Translational Oncology|August 9, 2022
Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders InitiativeOluwadamilola Olaku, Barbara A Conley, S Percy Ivy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 19, 2010
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)Suresh S Ramalingam, Chandra P Belani, Philip C Mack, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2005
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactionsLawrence W Anderson, Jerry M Collins, Raymond W Klecker, et al.
Pageof 30